Table 3.
Composition of Cellular Products a
| PRP: Cellular Composition (Versus Whole Blood) | |
|---|---|
| Injection volume, mL | PRP: 5.12 ± 1.12 |
| Platelet, 103/μL | PRP: 2673.72 ± 1139.04 Whole blood: 177.56 ± 43.74 |
| WBC, 103/μL | PRP: 25.36 ± 13.27 Whole blood: 5.43 ± 1.49 |
| RBC, 106/μL | PRP: 0.37 ± 0.73 Whole blood: 3.66 ± 0.75 |
| Neutrophil, % | PRP: 12.33 ± 13.37 Whole blood: 57.29 ± 9.67 |
| Lymphocyte, % | PRP: 67.81 ± 12.45 Whole blood: 30.75 ± 8.34 |
| Monocyte, % | PRP: 18.66 ± 6.11 Whole blood: 8.75 ± 1.65 |
| PRP: Growth Factor Composition | |
| TGF-β, ng/dL | 126.07 ± 7.17 |
| VEGF, ng/dL | 1037.52 ± 774.08 |
| IGF-1, ng/dL | 47.60 ± 20.88 |
| PDGF, ng/dL | 31.22 ± 10.39 |
| MFAT: Cellular Composition | |
| Volume, mL | 7.92 ± 3.87 |
| Total nucleated cell count, million/mL | 3.56 ± 4.62 |
| Viability, % | 97.96 ± 1.33 |
a Data are reported as mean ± SD. IGF-1, insulin-like growth factor–1; MFAT, microfragmented adipose tissue; PDGF, platelet-derived growth factor; PRP, platelet-rich plasma; RBC, red blood cell; TGF-β, transforming growth factor–β; VEGF, vascular endothelial growth factor; WBC, white blood cell.